Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Collen

Showing results (681-690 of 715) with videos related to

Pageof 72
Sort By:
The American Journal of Cardiology|August 1, 1987
Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rateM Verstraete, A E Arnold, R W Brower, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 2001
Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspectsS J Van Cromphaut, M Dewerchin, J G Hoenderop, et al.
Circulation Research|October 27, 2001
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heartM Ver Heyen, S Heymans, G Antoons, et al.
Annals of Internal Medicine|August 15, 1991
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II TrialE G Bovill, M L Terrin, D C Stump, et al.
Circulation|May 1, 1988
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarctionE J Topol, R M Califf, B S George, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 12, 2000
HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- miceG Theilmeier, B De Geest, P P Van Veldhoven, et al.
Circulation|December 1, 1984
Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trialD Collen, E J Topol, A J Tiefenbrunn, et al.
Annals of the New York Academy of Sciences|April 15, 1997
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen systemP Carmeliet, L Moons, M Dewerchin, et al.
Journal of the American College of Cardiology|June 1, 1987
A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarctionE J Topol, D C Morris, R W Smalling, et al.
Molecular and Cellular Biology|May 29, 2000
Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and controls expression of the proendocrine gene ngn3P Jacquemin, S M Durviaux, J Jensen, et al.
Pageof 72

Showing results (681-690 of 715) with videos related to

Sort By:
Pageof 72
The American Journal of Cardiology|August 1, 1987
Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rateM Verstraete, A E Arnold, R W Brower, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 2001
Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspectsS J Van Cromphaut, M Dewerchin, J G Hoenderop, et al.
Circulation Research|October 27, 2001
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heartM Ver Heyen, S Heymans, G Antoons, et al.
Annals of Internal Medicine|August 15, 1991
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II TrialE G Bovill, M L Terrin, D C Stump, et al.
Circulation|May 1, 1988
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarctionE J Topol, R M Califf, B S George, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 12, 2000
HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- miceG Theilmeier, B De Geest, P P Van Veldhoven, et al.
Circulation|December 1, 1984
Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trialD Collen, E J Topol, A J Tiefenbrunn, et al.
Annals of the New York Academy of Sciences|April 15, 1997
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen systemP Carmeliet, L Moons, M Dewerchin, et al.
Journal of the American College of Cardiology|June 1, 1987
A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarctionE J Topol, D C Morris, R W Smalling, et al.
Molecular and Cellular Biology|May 29, 2000
Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and controls expression of the proendocrine gene ngn3P Jacquemin, S M Durviaux, J Jensen, et al.
Pageof 72